Six Hot Post Inauguration Trades: HSDT, INM, RGTI, EONR, QBTS, QUBT
DENVER, Colo., Jan 21, 2025 (247marketnews.com)- These are some of the hottest trades following yesterday’s inauguration.
Helius Medical (NASDAQ: HSDT), a neurotechnology company focused on innovative neuromodulation therapies for balance and gait deficits, has announced it has exceeded its enrollment target for its stroke registrational program. With 128 participants randomized as of December 31, 2024, the program is on track to reach the target of 150 participants by the end of January 2025.
InMed Pharmaceuticals (NASDAQ: INM) reported promising results from a long-term preclinical Alzheimer’s Disease (AD) study. INM-901 demonstrated a reduction in several markers of neuroinflammation, a known factor in Alzheimer’s development and progression.
Rigetti Computing (NASDAQ: RGTI), D-Wave Quantum (NYSE: QBTS), and Quantum Computing (NASDAQ: QUBT) seem to be rebounding from what appears to be an oversold reaction to NVIDIA CEO’s recent comments about quantum technology.
EON Resources (NYSE: EONR) is an independent upstream drill-baby-drill energy company with oil and gas properties in the Permian Basin.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (HSDT, INM, RGTI, QBTS, QUBT, EONR)
- InMode to Present at Baird 2025 Global Healthcare Conference
- Quantum Computing Inc. Reports Second Quarter 2025 Financial Results
- InMode to Participate in Upcoming Investor Conferences
- Don’t Miss Out: MoBot’s Latest Stock Updates 08/04/25 08:00 AM
- INmune Bio’s INKmune CaRe PC Trial in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints